Amid the bitter divisions of our time—the reflexive politicization of nearly everything—there remains at least one area of universal consensus: that we must find cures for the diseases that devastate us most. Cancer. Rare conditions. Illnesses that have yet to yield to the standard of care. On this, we agree.
And yet the data that could accelerate those cures sits locked away—guarded, scattered, or impossible to find. Healthcare institutions, pharmaceutical companies, payors, and hospital systems treat it as a competitive asset. Patients, reasonably, fear what exposure of their most intimate information might mean. Physicians, already overwhelmed, have little bandwidth to engage. The justifications are real, and in isolation, each one is defensible.
But defensible is not the same as costless.
Outcome data about alternative treatments that is never shared represents a therapy delayed, a pattern unrecognized, a patient who ran out of time before the system found its answer. The moral weight of that delay belongs to all of us—for the healthcare system we have built, tolerated, and failed to challenge.
We are not short on data, evidence, or knowledge. We are short on the will to share it. That is a choice. And choices have consequences.